ERBB2 and breast carcinoma: Approximately 20% of breast cancers express HER2 and the development and clinical use of a monoclonal antibody against HER2 (Trastuzumab/Herceptin or Lapatinib/Tykerb) has considerably improved survival outcomes for these patients.